Current in-vivo models of coronavirus infection involving the use of ICIs have assessed anti-PD-L1 (100 μg, unreported administration route) treatment 1 day before and after SARS-CoV-2 infection (unreported concentration and administration route) in adeno-associated virus (AAV)-expressing human ACE2 mice (72) or the administration of anti-PD-1 (200 μg, IP) for 3 days commencing upon MHV-A59 infection (800 PFU, IP) (73). This evidence concerns the gene PDCD1 and infection.